Cargando…

Early serial circulating tumor DNA sequencing predicts the efficacy of chemohormonal therapy in patients with metastatic hormone-sensitive prostate cancer

Chemohormonal therapy is a standard treatment for metastatic hormone-sensitive prostate cancer (mHSPC); however, there are no biomarkers to guide clinical decisions regarding therapeutic options. We aimed to evaluate the clinical utility of serial circulating tumor DNA (ctDNA) sequencing in early pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Xinxing, Fei, Xiaochen, Wang, Jialin, Dong, Yanhao, Fan, Liancheng, Yang, Bin, Chen, Wei, Gong, Yiming, Xia, Binbin, Zhu, Hanjing, Wu, Fan, Wang, Yanqing, Dong, Liang, Zhu, Yinjie, Pan, Jiahua, Yao, Xudong, Dong, Baijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236461/ https://www.ncbi.nlm.nih.gov/pubmed/37247504 http://dx.doi.org/10.1016/j.tranon.2023.101701

Ejemplares similares

Early Plasma Circulating Tumor DNA as a Potential Biomarker of Disease Recurrence in Non-metastatic Prostate Cancer
por: Fei, Xiaochen, et al.
Publicado: (2023)

Transcriptomic signature defines two subtypes of locally advanced PCa with distinct neoadjuvant therapy benefits
por: Zhu, Yinjie, et al.
Publicado: (2023)

Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations
por: Chi, Chenfei, et al.
Publicado: (2022)

The prevalence and clinical implication of rare germline deleterious alterations in Chinese patients with prostate cancer: A real‐world multicenter study
por: Fei, Xiaochen, et al.
Publicado: (2021)

Extended lymphadenectomy for high-risk prostate cancer in patients with chronic lymphocytic leukemia may not be necessary: a report of two cases
por: Zhu, Yinjie, et al.
Publicado: (2019)

Albumin and Fibrinogen Combined Prognostic Grade Predicts Prognosis of Patients with Prostate Cancer
por: Wang, Yanqing, et al.
Publicado: (2017)

Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors
por: Fan, Liancheng, et al.
Publicado: (2018)

Engineering the MoS(2)/MXene Heterostructure for Precise and Noninvasive Diagnosis of Prostate Cancer with Clinical Specimens
por: Xie, Shaowei, et al.
Publicado: (2023)

Serum Pre-Albumin Predicts the Clinical Outcome in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone
por: Fan, Liancheng, et al.
Publicado: (2017)

Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy
por: Wang, Yanqing, et al.
Publicado: (2016)

Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma
por: Jeong, Il Seok Daniel, et al.
Publicado: (2020)

Surface-enhanced Raman spectroscopy before radical prostatectomy predicts biochemical recurrence better than CAPRA-S
por: Pan, Jiahua, et al.
Publicado: (2019)

Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer
por: Dong, Baijun, et al.
Publicado: (2020)

Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer
por: Sugino, Fumiya, et al.
Publicado: (2023)

Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer
por: Aguiar, Pedro Nazareth, et al.
Publicado: (2017)

Discovery of extracellular vesicles derived miR-181a-5p in patient's serum as an indicator for bone-metastatic prostate cancer
por: Wang, Yanqing, et al.
Publicado: (2021)

Neoadjuvant Chemohormonal Therapy in Prostate Cancer Before Radical Prostatectomy: A Systematic Review and Meta-Analysis
por: Ge, Qingyu, et al.
Publicado: (2022)

The Diagnostic Value of PI-RADS v2.1 in Patients with a History of Transurethral Resection of the Prostate (TURP)
por: Liu, Jiazhou, et al.
Publicado: (2022)

Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer
por: Babst, Christa, et al.
Publicado: (2022)

m(6)A-induced repression of SIAH1 facilitates alternative splicing of androgen receptor variant 7 by regulating CPSF1
por: Xia, Lei, et al.
Publicado: (2022)

AB140. Efficacy of radical prostatectomy combined with neoadjuvant chemotherapy in the treatment of locally advanced prostate cancer: preliminary experiences from a single center
por: Xue, Wei, et al.
Publicado: (2016)

Identification of characteristic metabolic panels for different stages of prostate cancer by (1)H NMR-based metabolomics analysis
por: Zhang, Xi, et al.
Publicado: (2022)

Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer
por: Sasaki, Takeshi, et al.
Publicado: (2021)

Clinical efficacy of neoadjuvant chemohormonal therapy combined with laparoscopic radical prostatectomy in high-risk Prostate Cancer
por: Zhang, Peng, et al.
Publicado: (2022)

PRKAR2B‐HIF‐1α loop promotes aerobic glycolysis and tumour growth in prostate cancer
por: Xia, Lei, et al.
Publicado: (2020)

CT‐based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration‐naïve oligometastatic prostate cancer
por: Sheikhbahaei, Sara, et al.
Publicado: (2020)

The Microbiome of Prostate Fluid Is Associated With Prostate Cancer
por: Ma, Xiaowei, et al.
Publicado: (2019)

Decreased TSPAN1 promotes prostate cancer progression and is a marker for early biochemical recurrence after radical prostatectomy
por: Xu, Fan, et al.
Publicado: (2016)

Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer
por: Matsuda, Yoshinori, et al.
Publicado: (2020)

Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapy
por: Iwamura, Hiromichi, et al.
Publicado: (2022)

E-cadherin bridges cell polarity and spindle orientation to ensure prostate epithelial integrity and prevent carcinogenesis in vivo
por: Wang, Xue, et al.
Publicado: (2018)

Comparison of neoadjuvant chemohormonal therapy vs. extended pelvic lymph-node dissection in high-risk prostate cancer treated with robot-assisted radical prostatectomy
por: Oishi, Takuya, et al.
Publicado: (2023)

CXCL1-LCN2 paracrine axis promotes progression of prostate cancer via the Src activation and epithelial-mesenchymal transition
por: Lu, Yongning, et al.
Publicado: (2019)

Influence of Seasonality and Circulating Cytokines on Serial QuantiFERON Discordances
por: Griffin, Marsha L., et al.
Publicado: (2018)

The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer
por: Ji, Yiyi, et al.
Publicado: (2023)

Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease
por: Suzuki, Hiroyoshi, et al.
Publicado: (2021)

PRKAR2B plays an oncogenic role in the castration-resistant prostate cancer
por: Sha, Jianjun, et al.
Publicado: (2016)

Circulating sex hormone levels in relation to male sperm quality
por: Zhao, Wei, et al.
Publicado: (2020)

Fracturing Behaviors and Mechanism of Serial Coal Pillar Specimens with Different Strength
por: Song, Cheng, et al.
Publicado: (2023)

Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study
por: Zhu, Gui‐Qi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d47n030t307oujq3i4d8modv3n